Churg-strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment.

Churg-strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment.

Semin Respir Crit Care Med. 2011 Jun;32(3):298-309

Authors: Dunogué B, Pagnoux C, Guillevin L

Churg-Strauss syndrome (CSS), first described in 1951, is a rare vasculitis of small- and medium-sized vessels. It is characterized by a constant association with asthma and eosinophilia, and by the presence of anti-myeloperoxidase (MPO) anti-neutrophil cytoplasmic antibodies (ANCA) in ~40% of the patients. Vasculitis typically develops in a previously asthmatic and eosinophilic middle-aged patient and most frequently involves the peripheral nerves and skin. Other organs, however, may be affected and must be screened for vasculitis, especially those associated with a poorer prognosis, such as the heart, kidney, and gastrointestinal tract, as assessed by the recently revised Five-Factor Score (FFS). Overall survival of CSS patients is excellent, but relapses are not uncommon and require maintenance or steroid-sparing therapies, depending on the original FFS-based prognosis at diagnosis. All patients require corticosteroids, often for prolonged periods, combined with immunosuppressants [e.g., induction (cyclophosphamide) and maintenance therapy (azathioprine)], for those with poorer prognoses. Recent insights, especially concerning clinical differences associated with ANCA status, showed that CSS patients might constitute a heterogeneous group, both clinically and pathogenically. Future therapies might reflect these differences more strongly.

PMID: 21674415 [PubMed – in process]

View full post on pubmed: asthma

Landmark Study Affirms the Clinical Utility of ImmunoCAP Allergy Testing – Insurance News Net (press release)

Landmark Study Affirms the Clinical Utility of ImmunoCAP Allergy Testing
Insurance News Net (press release)
This wealth of information on allergies and asthma in the US was made possible by data collected from Quest Diagnostic's use of the ImmunoCAP Specific IgE blood test from Phadia, the market leading in vitro allergy diagnostic test.

and more »

View full post on asthma – Google News

Anti-leukotrienes equivalent to standard asthma care – Clinical Advisor


FOX43.com

Anti-leukotrienes equivalent to standard asthma care
Clinical Advisor
Leukotriene-receptor antagonists were just as effective as inhaled glucocorticoids as first-line controller and add-on asthma therapy in a diverse primary care patient population, results from two “real-life” trials indicate.
Leukotriene antagonist pills 'preferred by asthma patients'Pulse
Asthma pills may work just as well as inhalers in the real worldLos Angeles Times
Asthma pills as good as inhaler: studyReuters
Nurse.com –CTV.ca –WebMD
all 143 news articles »

View full post on asthma – Google News

Clinical trials start for ABI’s breath asthma check rapid assay – Stock Market Wire

Clinical trials start for ABI's breath asthma check rapid assay
Stock Market Wire
StockMarketWire.com – Clinical trials for Akers Biosciences' breath asthma check rapid assay have begun in Clearwater, Florida. The trials have been designed to provide the clinical information to be included in a submission for regulatory approvals
18 APRIL 2011 Akers Biosciences* AKR (FTSE AIM All Share) 4p BUY (TP-10p)AngelNews (press release) (subscription)

all 3 news articles »

View full post on asthma – Google News

FDA Requests Clinical Trials to Test Asthma Drugs Symbicort, Advair – DrugWatch.com

FDA Requests Clinical Trials to Test Asthma Drugs Symbicort, Advair
DrugWatch.com
On April 15, the Food and Drug Administration (FDA) announced that the drug makers of the popular asthma medications Symbicort, Advair Diskus, Dulera and Foradil will be required to conduct clinical trials to test the medications.
FDA orders safety studies for some asthma drugsReuters
FDA Drug Safety Communication: FDA requires post-market safety trials for Long Bioscience Technology

all 12 news articles »

View full post on asthma – Google News

Harvard Clinical Research Institute Initiates Comparative Effectiveness Study … – Business Wire (press release)

Harvard Clinical Research Institute Initiates Comparative Effectiveness Study
Business Wire (press release)
Tiotropium) Study, the purpose of which is to investigate whether Black patients with asthma are more likely to experience adverse outcomes as a result of long-acting beta-agonist (LABA) therapy. The BELT study was funded by a grant from the Agency for

and more »

View full post on asthma – Google News